MYELODYSPLASTIC SYNDROMES (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to make risky transplants safer for blood cancer patients
Disease control Recruiting nowThis study tests a new combination of drugs (bendamustine and cyclophosphamide) to prevent graft-versus-host disease and a dangerous immune reaction after stem cell transplants. It involves 60 adults with high-risk blood cancers who have a partially matched donor. The goal is to …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated May 01, 2026 15:38 UTC
-
New hope for rare bone marrow cancer: targeted pill vs standard care
Disease control Recruiting nowThis study tests a daily pill (ivosidenib) against a standard shot (azacitidine) in 48 adults with a specific genetic form of myelodysplastic syndromes (MDS) who haven't had prior treatment. The goal is to see which better controls the disease by improving blood counts and reduci…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New hope for hard-to-treat blood cancers?
Disease control Recruiting nowThis early-phase study tests a new drug called ICP-248 combined with a standard medicine (azacitidine) for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goals are to find a safe dose and see if the combo helps control the disease. About 266…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC